89bio Inc Ordinary Shares ETNB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ETNB is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $9.66
- Day Range
- $9.19–9.85
- 52-Week Range
- $6.58–18.30
- Bid/Ask
- $9.23 / $9.63
- Market Cap
- $909.07 Mil
- Volume/Avg
- 628,609 / 992,691
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 70
- Website
- https://www.89bio.com
Comparables
Valuation
|
Metric
|
ETNB
|
IMVT
|
SLRN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.72 | 6.86 | 1.07 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ETNB
|
IMVT
|
SLRN
|
|---|---|---|---|
Quick Ratio | 14.70 | 13.18 | 13.08 |
Current Ratio | 15.03 | 13.70 | 13.27 |
Interest Coverage | −50.24 | — | — |
Quick Ratio
ETNB
IMVT
SLRN
Profitability
|
Metric
|
ETNB
|
IMVT
|
SLRN
|
|---|---|---|---|
Return on Assets (Normalized) | −28.84% | −44.70% | −28.15% |
Return on Equity (Normalized) | −32.23% | −49.06% | −35.30% |
Return on Invested Capital (Normalized) | −33.57% | −53.44% | −41.97% |
Return on Assets
ETNB
IMVT
SLRN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Zdnvgkpwx | Qjgs | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Mngwjpyw | Rbvpfr | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Lydcjlptr | Nnsvh | $118.7 Bil | |||
| Moderna Inc
MRNA
| Xjnmzvs | Pgdz | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kgstkjqm | Mbjsbg | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Xsdfqvyv | Pqp | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Ngnhvst | Qphyp | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Kwwvmvjk | Qvjcq | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Fgdsvhkd | Sgnv | $15.0 Bil | |||
| Incyte Corp
INCY
| Khghltr | Bcbwr | $13.5 Bil |